Jared C. Robins, M.D., Andrew F. Khair, Ph.D., M.B.A., Eric A. Widra, M.D., Michael M. Alper, M.D., Winnie W. Nelson, Pharm.D., M.S., M.B.A., Eric D. Foster, Ph.D., Anshul Sinha, B.Tech., Masakazu Ando, Ph.D., Patrick W. Heiser, Ph.D., Gaurang S. Daftary, M.D., M.B.A.
To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial.
Cost minimization analysis of trial results.
Thirty-one fertility centers.
Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL.
Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization.
Main Outcome Measure(s)
Mean cost of achieving live birth after first transfer (fresh or frozen).
First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH.
Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH.
Clinical Trial Registration Number